

VistaGen Therapeutics, Inc.  
Form SC 13G/A  
July 01, 2016

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13G/A  
Under the Securities Exchange Act of 1934  
(Amendment No. 1)\***

(Name of Issuer) **VISTAGEN THERAPEUTICS, INC.**

(Title of Class of Securities) **Common Stock, par value \$0.001 per share**

(CUSIP Number) **92840H202**

(Date of Event Which Requires Filing of this Statement) **June 24 , 2016**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

---

CUSIP No. **92840H202**

Edgar Filing: VistaGen Therapeutics, Inc. - Form SC 13G/A

(1) Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

Calm Seas Capital

261342718

(2) Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

(3) SEC Use Only

(4) Citizenship or Place of Organization

Nevada

(5) Sole Voting Power

Number of

0

Shares (6) Shared Voting Power

Beneficially

Owned by

170,257

Each (7) Sole Dispositive Power

Reporting

Person

0

(8) Shared Dispositive Power

With

170,257

(9) Aggregate Amount Beneficially Owned by Each Reporting Person

170,257

(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]

(See Instructions)

(11) Percent of Class Represented by Amount in Row (9)

2.14%

(12) Type of Reporting Person (See Instructions)

OO

CUSIP No. **92840H202**

(1) Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

Michael McCarthy

(2) Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

(3) SEC Use Only

(4) Citizenship or Place of Organization

United States

(5) Sole Voting Power

Number of

0

Shares (6) Shared Voting Power

Beneficially

Owned by

170,257

Each (7) Sole Dispositive Power

Reporting

Person

0

(8) Shared Dispositive Power

With

170,257

(9) Aggregate Amount Beneficially Owned by Each Reporting Person

170,257

(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares [ ]

(See Instructions)

(11) Percent of Class Represented by Amount in Row (9)

2.14%

(12) Type of Reporting Person (See Instructions)

IN

**Item 1.**

**(a) Name of Issuer**

VISTAGEN THERAPEUTICS, INC.

**(b) Address of Issuer's Principal Executive Offices**

343 Allerton Avenue

South San Francisco, California, 94080

**Item 2.**

**(a) Name of Person Filing**

Calm Seas Capital

Michael McCarthy

**(b) Address of Principal Business Office or, if none, Residence**

4650 Wedekind Rd. Suite 2

Sparks, NV 89431

**(c) Citizenship**

United States

**(d) Title of Class of Securities**

Common Stock, par value \$0.001 per share

**(e) CUSIP Number**

92840H202

**Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

**(a)**

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

**(b)**

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

**(c)**

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

**(d)**

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

**(e)**

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

**(f)**

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

**(g)**

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

**(h)**

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

**(i)**

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

**(j)**

Group, in accordance with §240.13d-1(b)(1)(ii)(J).

**Item 4.**

**(a) Amount beneficially owned:**

Calm Seas Capital beneficially owns 170,257 shares of the Issuer's common stock.

Mr. Michael McCarthy is the Managing Director of Calm Seas Capital and has voting and dispositive power over the securities described above.

**(b) Percent of class:**

2.14%. Based on 7,970,705 shares of the Issuer's common stock outstanding on June 22, 2016, as reported by VistaGen Therapeutics, Inc. in its Annual Report on Form 10-K for the year ended March 31, 2016.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote**

0

**(ii) Shared power to vote or to direct the vote**

170,257

**(iii) Sole power to dispose or to direct the disposition of**

0

**(iv) Shared power to dispose or to direct the disposition of**

170,257

**Item 5. Ownership of Five Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

N/A

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

N/A

**Item 8. Identification and Classification of Members of the Group.**

N/A

**Item 9. Notice of Dissolution of Group.**

N/A

**Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

---

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: *July 1, 2016*

Calm Seas Capital

By: */s/ Michael McCarthy*

---

*Name: Michael McCarthy*

*Title: Managing Director*

---